ArticleTuberculosis and respiratory diseases2026
Changing Epidemiology of Severe Pneumococcal Pneumonia in Adults at a Tertiary Hospital between 2010 and 2024.
Article in Tuberculosis and respiratory diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe epidemiology of pneumococcal pneumonia can be influenced by vaccine implementation, serotype replacement, and viral circulation. We aimed to investigate 15-year trends in the epidemiological and clinical characteristics of severe pneumococcal pneumonia patients requiring intensive care unit (ICU) admission.
methodsWe analyzed data from a prospective cohort of adult patients with severe pneumonia admitted to the 28-bed medical ICU of a 2,700-bed tertiary hospital in South Korea between 2010 and 2024. Temporal changes in incidence, resistance to antimicrobial agents, frequency of coinfections, and mortality were evaluated across three 5-year periods.
resultsAmong 2,511 ICU patients with severe pneumonia, 140 (5.6%) had pneumococcal infections. The proportion of pneumococcal cases decreased from 9.9% in 2010-2014 to 4.2% in 2015-2019, and further to 2.2% in 2020-2024 (p<0.001 for trend). Conversely, ceftriaxone non-susceptibility rates rose sharply from 4.8% to 16.7% and 45.5% across the same periods (p<0.001). Coinfections were frequent and increased significantly, largely due to respiratory viruses, with rates of 48.9%, 61.8%, and 77.8%, respectively (p=0.02). Influenza was the predominant co-pathogen during 2015-2019, whereas severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was most frequent in 2020-2024. The 90-day mortality rates remained stable over time (29.5%, 38.2%, and 27.8%, p=0.64).
conclusionIn this single-center ICU cohort, the proportion of severe pneumococcal pneumonia cases decreased over the 15-year period, whereas ceftriaxone non-susceptibility and viral coinfections became more frequent. These trends should be interpreted cautiously given the lack of serotype and individual vaccination data and incomplete susceptibility results. Continued surveillance of pneumococcal disease, antimicrobial resistance, and respiratory coinfections is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.